Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan-Dec:18:17539447241295957.
doi: 10.1177/17539447241295957.

What's new in cardiac amyloidosis? Pharmacological treatment, physical activity, and care of patients with transthyretin cardiac amyloidosis

Ezequiel J Zaidel  1 , Sol C Song  2 , Juan J Sterba  1 , Agustina Piccinato  1 , María Candelaria Ramos  1 , Silvina L Cacia  1
Affiliations
Review

What's new in cardiac amyloidosis? Pharmacological treatment, physical activity, and care of patients with transthyretin cardiac amyloidosis

Ezequiel J Zaidel et al. Ther Adv Cardiovasc Dis. 2024 Jan-Dec.

Abstract

Awareness, proper diagnosis and treatment of cardiac amyloidosis have increased, but there are still several unmet needs that have to be addressed for the optimal care of the disease. In this comprehensive review, we describe current and future treatments for both hereditary and wild-type TTR cardiac amyloidosis and also review lifestyle, including current challenges and opportunities for specific dietary concerns and exercise sports for these patients.

Keywords: cardiac amyloidosis; cardiomyopathy; disease-modifying agents; heart failure; small interfering RNA.

PubMed Disclaimer

Conflict of interest statement

EJZ received prior consultant or speaker fees from Astra Zeneca, PTC therapeutics, and Pfizer, not related to this publication. The rest of the authors have none to declare.

Figures

Figure 1.
Figure 1.
Actual therapies for ATTR-CM. Source: Icons made by Freepik from www.flaticon.com. *In study. **Tafamidis demonstrated a reduction in mortality and hospitalizations in a phase III study. ASO, antisense oligonucleotide; ATTR-CM, transthyretin amyloid cardiomyopathy; TTR, transthyretin; siRNA, small interfering RNA.
Figure 2.
Figure 2.
Pharmacological therapies.
See this image and copyright information in PMC

References

    1. Maurer MS, Bokhari S, Damy T, et al.. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019; 12(9): e006075. - PMC - PubMed
    1. Carretero M, Aguirre MA, Villanueva E, et al.. Características y evolución de los pacientes con amiloidosis sistémica y compromiso cardíaco [Features and evolution of patients with systemic amyloidosis and cardiac involvement]. Arch Cardiol Mex 2022; 92(1): 60–67. - PMC - PubMed
    1. Lado Lado FL, Ferreiro Regueiro ML, Cabana González B, et al.. Amiloidosis. Medicina Integral 2000; 36(4): 137–141.
    1. Koike H, Okumura T, Murohara T, et al.. Multidisciplinary approaches for transthyretin amyloidosis. Cardiol Ther 2021; 10(2): 289–311. - PMC - PubMed
    1. González-Lópeza E, López-Sainza A, Garcia-Pavia P. Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza. Revista Española de Cardiología 2017; 70: 991–1004 - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources